Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol.

The antiviral drug arbidol (ARB), which is licensed in Russia for use against influenza, is known to inhibit early membrane fusion events in influenza A and B virus replication. To investigate in more detail the target and mechanism of ARB action we generated and studied the characteristics of ARB-resistant influenza virus mutants. Observations of the ARB susceptibility of reassortants between A/Singapore/1/57(H2N2) and A/chicken/Germany/27(H7N7, "Weybridge" strain) and of mutants of the latter virus identified the virus haemagglutinin (HA) as the major determinant of ARB sensitivity. ARB-resistant mutants, selected from the most sensitive reassortant, possessed single amino acid substitutions in the HA2 subunit which caused an increase in the pH of fusion and the associated conformational change in HA. ARB was shown to stabilize the HA by causing a 0.2 pH unit reduction in the pH of the transition to the low pH form, which was specifically abrogated by the resistance mutations. Some of the resistance mutations, which reduce acid stability and would disrupt ARB-HA interactions, are located in the vicinity of a potential ARB binding site identified using the docking programme Gold. Together, the results of these investigations indicate that ARB falls within a class of inhibitor which interacts with HA to stabilize it against the low pH transition to its fusogenic state and consequently inhibit HA-mediated membrane fusion during influenza virus infection.

[1]  D. Richman,et al.  Antiviral drug resistance. , 2006, Antiviral research.

[2]  R. Sidwell,et al.  Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.

[3]  D. M. Zlydnikov,et al.  Study of rimantadine in the USSR: a review of the literature. , 1981, Reviews of infectious diseases.

[4]  R. Webster,et al.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en , 1996, Journal of virology.

[5]  N. Meanwell,et al.  Taking aim at a moving target-inhibitors of influenza virus Part 1 : virus adsorption, entry and uncoating , 1996 .

[6]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[7]  I D Kuntz,et al.  Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. , 1993, Biochemistry.

[8]  I D Kuntz,et al.  Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity , 1997, Journal of virology.

[9]  S. Trottier,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.

[10]  A. Douglas,et al.  Specific structural alteration of the influenza haemagglutinin by amantadine. , 1990, The EMBO journal.

[11]  J. Farrar,et al.  Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. , 2005, The New England journal of medicine.

[12]  C B Hall,et al.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection , 1988, Journal of virology.

[13]  J. Skehel,et al.  H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. , 2004, Virology.

[14]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[15]  M. Zambon,et al.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[16]  Shuster Am,et al.  Efficacy of arbidol in prophylaxis and treatment of acute respiratory viral infections in servicemen , 2002 .

[17]  G L Ada,et al.  Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). , 1997, Vaccine.

[18]  R. G. Glushkov,et al.  [Sensitivity of influenza A/H5 viruses isolated from wild birds on the territory of Russia to arbidol in the cultured MDCK cells]. , 2005, Voprosy virusologii.

[19]  I. Wilson,et al.  Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[21]  R. Nilakantan,et al.  Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. , 1999, Journal of virology.

[22]  R. Belshe,et al.  Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. , 1993, The Journal of infectious diseases.

[23]  R. G. Glushkov,et al.  [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]. , 2005, Terapevticheskii arkhiv.

[24]  R. Webster,et al.  A pandemic warning? , 1997, Nature.

[25]  A. Monto,et al.  Effectiveness of Inactivated Influenza Vaccine Among Nursing Home Residents During an Influenza Type A (H3N2) Epidemic , 1999, Journal of the American Geriatrics Society.

[26]  N. Meanwell,et al.  pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion , 1999, Journal of Virology.

[27]  H. Xiao,et al.  Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo , 2007, Archives of Virology.

[28]  J. Skehel,et al.  Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. , 1994, The Journal of general virology.

[29]  N. Meanwell,et al.  Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus , 1997, Journal of virology.

[30]  B. Margolis,et al.  Phosphatidylinositol 3′‐kinase is activated by association with IRS‐1 during insulin stimulation. , 1992, The EMBO journal.

[31]  D M Fleming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. , 1997, The New England journal of medicine.

[32]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[33]  S. Polyak,et al.  Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. , 2008, Current medicinal chemistry.

[34]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[35]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[36]  M. Krystal,et al.  Characterization of a hemagglutinin-specific inhibitor of influenza A virus. , 1996, Virology.

[37]  D. Wiley,et al.  Fusion mutants of the influenza virus hemagglutinin glycoprotein , 1985, Cell.

[38]  A. Hay,et al.  Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. , 1992, Virology.

[39]  R. Douglas,et al.  Prophylaxis and treatment of influenza. , 1990, The New England journal of medicine.

[40]  D. Barnard,et al.  Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. , 1998, Antiviral research.

[41]  A. Hay,et al.  Maturation of influenza A virus hemagglutinin--estimates of the pH encountered during transport and its regulation by the M2 protein. , 1992, Virology.